New MHRA guidance concerning sodium valproate and pregnancy risks
Today the Medicines and Healthcare Products Regulatory Authority (MHRA) launched a brand new toolkit, to help ensure that women are properly informed, before they become pregnant, of the risks to their unborn child if they take sodium valproate during pregnancy. You can see it here!
The toolkit was developed with the input of a number of patient organisations, including Epilepsy Research UK, who welcome the initiative.
Click here to read the MHRA’s official press release marking today’s launch!